

# The Microbe Blotter: **Multiple Arrests Made**

A Patient with Fever after Chemotherapy

**(PART 2)**

Judy Streit, MD


Silvie Kremserova, PhD

Special ID Grand Rounds


May 4, 2017

# Human parvovirus B19

- Small, non-envelope, single stranded DNA virus (*Parvoviridae*)
- Extremely resistant to physical inactivation
- Important viral proteins - structural proteins VP1, VP2,
  - nonstructural proteins NS1, 11kDa, 7.5kDa




- Strong tropism to **erythroid progenitor cells (EPCs)**



# Questions:

- 1. Why is Parvovirus B19 tropic for certain cell types?
- 2. What are the effects of B19 on erythroid precursors (or other cells impacted by infection), and what is their pathogenesis?
- 3. What clinical significance, if any, is proposed as the result of long-lasting B19 infection?

# Virus entrance into a host cell



1. Attachment
2. Penetration
3. DNA replication
4. Protein translation
5. Assembly of virions
6. Cell lysis

# Factors responsible for tropism of B19 infection

- Receptor **P antigen** (globoside, Gb4): binding

{Brown KE, Anderson SM, Young NS; 1993}

- Co-receptors: binding and entry


**$\alpha 5/\beta 1$ -integrin**

{Kirsten A et al; 2003}


**Ku80**

{Munakata Y et al; 2005}

- **Erythroid progenitor cells (EPCs)**




# B19 replication is occurs in the cell nucleus



Primary human erythroid cells


Mature human RBCs

Weigel-Kelly K.A. et al., Blood 2003; 102(12):3927-33



# P antigen is present also on non-erythroid cells

P antigen (Gb4) expression




- megakaryocytes
- endothelial cells
- placenta
- fetal liver
- heart cells


**Not all P antigen-expressing cells are permissive to infection by B19**

# Human hematopoietic cell lines


## P antigen expression



## Viral binding



Level of P antigen expression does not correlate with the efficiency of viral binding





# Factors responsible for tropism of B19 infection

- Receptor **P antigen** (globoside, Gb4): binding

{Brown KE, Anderson SM, Young NS; 1993}

- Co-receptors: binding and entry

**$\alpha$ 5/ $\beta$ 1-integrin**

{Kirsten A et al; 2003}


**Ku80**

{Munakata Y et al; 2005}

- **Erythroid progenitor cells (EPCs)**
- **Circulating angiogenic cells (CACs)**

# CACs – receptor & co-receptors

A




eo-EPCs = early outgrowth epithelial progenitor cells  
ECFCs = endothelial colony-forming cells  
CFU Hill = colony-forming unit Hill  
KDR = kinase insert domain receptor


# Questions:

- 1. Why is Parvovirus B19 tropic for certain cell types?
- 2. What are the effects of B19 on erythroid precursors (or other cells impacted by infection), and what is their pathogenesis?
- 3. What clinical significance, if any, is proposed as the result of long-lasting B19 infection?

# Parvovirus B19 infection disrupts erythropoiesis




# How...?




1. Virus internalization into the cell

# How...?



1. Virus internalization into the cell
2. B19 DNA replication

# How...?



1. Virus internalization into the cell
2. B19 DNA replication
3. Apoptosis induction

# THE MICROBE BLOTTER

## Multiple Arrests Made


### S phase

- DNA is replicated

### G<sub>2</sub> phase


- Preparation for mitosis
- Rapid cell growth and protein synthesis
- the end of G<sub>2</sub> phase and mitotic entry is determined by a threshold level of active cyclin B1/CDK1 complex

**NS1 and 11kDa protein induce cell cycle arrest**






# NS1-induced G<sub>2</sub> phase arrest & ATR-CDK1 pathway



# Questions:

- 1. Why is Parvovirus B19 tropic for certain cell types?
- 2. What are the effects of B19 on erythroid precursors (or other cells impacted by infection), and what is their pathogenesis?
- 3. What clinical significance, if any, is proposed as the result of long-lasting B19 infection?

# Persistent B19 infection = viral DNA is present more than 6 months after onset of symptoms





Acute  $>10^{12}$  IU/mL  
Persistent  $< 10^4$  IU/mL

## Immunocompromised individuals

No neutralizing antibody  
Chronic red cell aplasia

**B19 Viremia & Antibody Responses**




# Persistent B19 infection


= viral DNA is present more than 6 months after onset of symptoms

Acute  $>10^{12}$  IU/mL

Persistent  $< 10^4$  IU/mL



## Immunocompromised individuals



## Immunocompetent individuals

- non-symptomatic

B19 mostly in tissues than in bone marrow

No viremia or anti-B19 IgM

Virus persist without replicating

- symptomatic


Myocarditis, cardiomyopathy

Chronic arthropathy

Liver failure

# Chronic red cell aplasia

- In immunocompromised patients
- Depletion of erythroid precursors in bone marrow
- Symptoms are generally not present



**More common long-term persistency of B19 is in non-erythroid cells/tissues**

# Cardiomyopathy


- B19 is a common pathogen in microvascular disease and cardiomyopathy
- Bone marrow-derived circulating angiogenic cells (CACs) = similarity with EPCs

CACs are characterized by surface antigen expression:


**CD34** – hematopoietic marker

**KDR** (kinase insert domain receptor) – endothelial marker

# Cardiomyopathy and CACs



# B19 induces apoptosis of CACs in cardiomyopathic patients





# Persistent B19 infection & diseases

- In 13 of 50 (26%) bone marrow samples from rheumatic patients indicating persistent infection

{Lundqvist A et al; 2005}

- Low-level viral gene expression occurs in some persistently infected cells

Bone marrow

Heart

Kidney

Liver – chronic hepatitis

Lymphoid

Thyroid tissues

{Mogensen TH et al; 2010}

{Adamson-Small LA et al; 2014}

**presence of B19V DNA in blood not necessarily correlates with active B19 replication**

# Summary

